Last reviewed · How we verify
Fluzone® 2009-2010 Formula
Fluzone® 2009-2010 Formula is a Biologic drug developed by Stanford University. It is currently FDA-approved. Also known as: Trivalent inactivated influenza vaccine (TIV), FDA-licensed seasonal influenza vaccine.
Fluzone 2009-2010 Formula is a vaccine used to prevent influenza. It was studied in clinical trials, including one conducted by Stanford University, to evaluate its effectiveness in inducing B-cell immunity against the flu.
At a glance
| Generic name | Fluzone® 2009-2010 Formula |
|---|---|
| Also known as | Trivalent inactivated influenza vaccine (TIV), FDA-licensed seasonal influenza vaccine |
| Sponsor | Stanford University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluzone® 2009-2010 Formula CI brief — competitive landscape report
- Fluzone® 2009-2010 Formula updates RSS · CI watch RSS
- Stanford University portfolio CI
Frequently asked questions about Fluzone® 2009-2010 Formula
What is Fluzone® 2009-2010 Formula?
Who makes Fluzone® 2009-2010 Formula?
Is Fluzone® 2009-2010 Formula also known as anything else?
What development phase is Fluzone® 2009-2010 Formula in?
Related
- Manufacturer: Stanford University — full pipeline
- Also known as: Trivalent inactivated influenza vaccine (TIV), FDA-licensed seasonal influenza vaccine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing